Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 5 | 2020 | 14 | 1.390 |
Why?
|
| Gynecology | 3 | 2018 | 9 | 0.960 |
Why?
|
| Medical Oncology | 3 | 2018 | 42 | 0.930 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 70 | 0.750 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 38 | 0.580 |
Why?
|
| Registries | 1 | 2018 | 188 | 0.540 |
Why?
|
| Endometrial Neoplasms | 3 | 2022 | 13 | 0.530 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2022 | 82 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 122 | 0.390 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 35 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 241 | 0.340 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 506 | 0.250 |
Why?
|
| Female | 15 | 2022 | 15730 | 0.240 |
Why?
|
| Mutation | 2 | 2022 | 353 | 0.200 |
Why?
|
| Paclitaxel | 2 | 2021 | 44 | 0.200 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 7 | 0.190 |
Why?
|
| Infertility, Female | 1 | 2021 | 13 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2021 | 33 | 0.190 |
Why?
|
| Humans | 15 | 2022 | 28436 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 206 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.160 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 1 | 0.160 |
Why?
|
| Hydrazines | 1 | 2018 | 7 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 9 | 0.160 |
Why?
|
| Dextrocardia | 1 | 2018 | 2 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 8 | 0.160 |
Why?
|
| Piperazines | 1 | 2019 | 80 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 12 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2018 | 119 | 0.150 |
Why?
|
| Certification | 1 | 2018 | 49 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 65 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 190 | 0.140 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1216 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2018 | 161 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 319 | 0.120 |
Why?
|
| Survival Rate | 2 | 2021 | 356 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 371 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 177 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 202 | 0.120 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 2 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 59 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 25 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 59 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2013 | 135 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2022 | 21 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 362 | 0.100 |
Why?
|
| Sirolimus | 2 | 2022 | 20 | 0.090 |
Why?
|
| United States | 1 | 2018 | 2201 | 0.090 |
Why?
|
| Middle Aged | 5 | 2019 | 9269 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 81 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 66 | 0.090 |
Why?
|
| Electronic Health Records | 2 | 2020 | 75 | 0.080 |
Why?
|
| Tomography, X-Ray | 1 | 2009 | 2 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 89 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2021 | 3615 | 0.070 |
Why?
|
| Adult | 3 | 2018 | 8107 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4857 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 661 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 9277 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 2069 | 0.060 |
Why?
|
| Strategic Planning | 1 | 2021 | 7 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 14 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2021 | 22 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3612 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 1 | 0.050 |
Why?
|
| Carboplatin | 1 | 2021 | 24 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 21 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 18 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 15 | 0.050 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 330 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 30 | 0.040 |
Why?
|
| Heart | 1 | 2018 | 69 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2016 | 57 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 79 | 0.030 |
Why?
|
| Metaplasia | 1 | 2013 | 7 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 52 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 313 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 492 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 440 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 390 | 0.020 |
Why?
|